Pharmacokinetics and Pharmacodynamics
A section of Pharmaceutics (ISSN 1999-4923).
Section Information
“Pharmacokinetics and Pharmacodynamics” is a Section of the peer-reviewed open access journal Pharmaceutics, which is devoted to highlighting the importance of pharmacokinetics and pharmacodynamics in drug development for better understanding of drug action. The Section welcomes original research articles as well as review papers that address a variety of related topics to novel and significant scientific findings by in vitro, in vivo, and clinical studies. The manuscript mainly focused on descriptive pharmacokinetics lacking novelty and scientific significance will not be considered for review.
Covered topics include:
- Mechanisms and factors affecting drug absorption, distribution, metabolism, and excretion;
- Kinetics of drug disposition and therapeutic effects;
- Pharmacokinetics, pharmacodynamics, and pharmacometrics;
- Toxicokinetics and toxicodynamics;
- Mathematical model for the assessment of drug ADME;
- Model-based drug development;
- Translational mathematical modeling in drug development;
- Quantitative systems pharmacology.
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Role of Pharmacokinetics in Drug Development and Evaluation (Deadline: 10 April 2023)
- Pediatric Drug Formulations (Deadline: 15 April 2023)
- Assessment of the Performance of Non-systemic Locally-Acting Drugs in the Gastrointestinal Tract (Deadline: 20 April 2023)
- Toxicokinetics in Renal Disease (Deadline: 20 April 2023)
- Drug Metabolism/Transport and Pharmacokinetics, Volume II (Deadline: 30 April 2023)
- Drug Interaction Mechanisms in Clinical Practice (Deadline: 30 April 2023)
- Adding Model-Informed Precision Dosing to Precision Medicine to Improve Patient Drug Treatment Outcomes (Deadline: 20 May 2023)
- Dosage Form Formulation Technologies for Improving Bioavailability (Deadline: 20 May 2023)
- Recent Advances in Natural Product Drugs (Deadline: 31 May 2023)
- Personalisation the Management of Inflammatory Diseases (Deadline: 1 June 2023)
- Novel Approaches for Optimizing Pharmacotherapy Based on Recent Pharmacokinetic, Pharmacodynamic, and Pharmacogenetic Developments (Deadline: 10 June 2023)
- Pharmacokinetics of Orally Administered Drugs (Volume II) (Deadline: 20 June 2023)
- Bioanalysis and Metabolomics (Volume II) (Deadline: 20 June 2023)
- Applications of Physiologically-Based Pharmacokinetic (PBPK) Modeling, Volume II (Deadline: 30 June 2023)
- Innovative In Vitro/In Silico Approaches to Drug Permeation and Absorption: The Highway to Implement the 3Rs Principles in Drug Development (Deadline: 30 June 2023)
- Research Progress of Nanomedicine and Its Pharmacokinetics (Deadline: 10 July 2023)
- Model-Informed Drug Discovery and Development—Volume II (Deadline: 20 July 2023)
- Population Pharmacokinetic Studies in Pediatrics (Deadline: 31 July 2023)
- Model-Based Drug Development for Diabetes Treatment (Deadline: 20 August 2023)
- Pharmaceutical Formulation for Improving Oral Bioavailability (Deadline: 20 August 2023)
- Physiologically-Based Pharmacokinetic Modeling in Pregnancy, Lactation, and in Neonates: Achievements, Challenges and Future Directions (Deadline: 1 September 2023)
- An Update on Pharmacogenomic and Pharmacogenetic Challenges in Cardiovascular Diseases and Psychiatric Disorders (Deadline: 15 September 2023)
- Pharmacokinetics of Nanomedicines (Deadline: 30 September 2023)
- Innovative Tools for Therapeutic Drug Monitoring Volume II (Deadline: 30 November 2023)
- Transport and Metabolism of Small-Molecule Drugs (Volume II) (Deadline: 30 November 2023)
- Pharmacokinetics, Pharmacodynamics and Drug Interactions (Deadline: 1 December 2023)
- Pharmacokinetics and Drug Interactions (Deadline: 31 December 2023)
- Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions Volume II (Deadline: 28 February 2024)
- Dose Optimization of Traditional and New Drug Formulations in Veterinary and Human Medicine (Deadline: 30 March 2024)
